Data collection in cancer clinical trials: Too much of a good thing?

Clinical Trials

Volumn 10, Issue 4, 2013, Pages 624-632

  O'Leary, Erin ^a   Seow, Hsien ^a,b   Julian, Jim ^a,b,c   Levine, Mark ^a,b,c   Pond, Gregory R ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b Escarpment Cancer Research Institute   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; INFORMATION PROCESSING; MEDICAL HISTORY; NEOPLASM; OUTCOME ASSESSMENT; PATIENT CARE; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; RETROSPECTIVE STUDY; SAMPLE SIZE; WORKLOAD;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; HUMANS; NEOPLASMS; ONTARIO; RETROSPECTIVE STUDIES;

EID: 84881063348     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513491337     Document Type: Article

References (17)

1. Canadian Cancer Research Alliance. Report on the state of cancer clinical trials in Canada. Report, 2011. Toronto, ON, Canada: CCRA.
2. Committee on Cancer Clinical Trials and the NCI Cooperative Group Program and Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. The National Academies Press,Washington, DC, 2010.
3. World Health Organization. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. Int Dig Health Legis 1997; 48(2): 231-34.
4. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol. 2003 ; 21 (22). 4145-50
5. Roche K, Paul N, Smuck B, et al. Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2002 ; 20 (2). 545-56
6. James P, Bebee P, Beekman L, et al. Effort tracking metrics provide data for optimal budgeting and workload management in therapeutic cancer clinical trials. J Natl Compr Canc Netw. 2011 ; 9 (12). 1343-52
7. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010 ; 28 (17). 2925-35
8. Sargent DJ, George SL. Clinical trials data collection: When less is more. J Clin Oncol. 2010 ; 28 (34). 5019-21
9. Marks RG. Validating electronic source data in clinical trials. Control Clin Trials. 2004 ; 25 (5). 437-46
10. Lauritsen K, Degl' IA, Hendel L, et al. Symptom recording in a randomised clinical trial: Paper diaries vs. electronic or telephone data capture. Control Clin Trials. 2004 ; 25 (6). 585-97
11. Kaiser LD, Melemed AS, Preston AJ, et al. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 ; 28 (34). 5046-53
12. Mahoney MR, Sargent DJ, O'Connell MJ, et al. Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol. 2005 ; 23 (36). 9275-81
13. Abrams J, Erwin R, Fyfe G, Schilsky RL. Data submission standards and evidence requirements. Oncologist. 2010 ; 15 (5). 488-91
14. Millum J, Menikoff J. Streamlining ethical review. Ann Intern Med. 2010 ; 153 (10). 655-57
15. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: Review of publications and survey of authors. BMJ. 2005 ; 330 (7494). 753
16. Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst. 2012 ; 104 (8). 590-98
17. Duley L, Antman K, Arena J, et al. Specific barriers to the conduct of randomized trials. Clin Trials. 2008 ; 5 (1). 40-48